Kornimate/medical-research-clean huggingface dataset:
study of ociperlimab plus tislelizumab plus chemoradiotherapy in participants with untreated limited-stage small cell lung cancer

Conditions: Limited Stage Small Cell Lung Cancer

Summary: this phase 2 trial examined whether the preliminary efficacy and safety of ociperlimab, tislelizumab, and ccrt when used in combination is expected to advance treatment options in the serious unmet medical need population of limited-stage small cell lung cancer (ls-sclc) participants .


Eligibility criteria:
key inclusion criteria: * participant has pathologically (histologically or cytologically) proven diagnosis of small cell lung cancer * has limited-stage disease (stage tx, t1-t4, n0-3, m0; ajcc staging, 8th edition), and can be safely treated with definitive radiation doses. * participant has not received any prior treatment for ls-sclc. * participant has measurable disease as assessed according to recist v1.1 that is appropriate for selection as a target lesion for repeat measurement, as determined by local site investigator/radiology review * ecog performance status ≤ 2 assessed within 7 days before the first administration of study intervention, and must have a life expectancy of ≥ 12 weeks. key exclusion criteria: * mixed small cell lung cancer histology. note: mixed sclc with the component of neuroendocrine carcinoma origin is considered eligible * have received surgical resection for ls-sclc * any participant for whom the tumor is considered resectable by surgery or stereotactic body radiation therapy/stereotactic ablative radiotherapy should be considered ineligible * is expected to require any other form of antineoplastic therapy while on study. * prior therapy with an anti-pd-1, anti-pd-l1, anti-pd-l2, anti-tigit, or any other antibody or drug specifically targeting t-cell costimulation or checkpoint pathways note: other protocol-defined inclusion/exclusion criteria may apply
comparison of prosthetic femoropopliteal bypass versus viabahn endoprosthesis for treatment of symptomatic femoral artery occlusion

Conditions: Atherosclerosis; Lower Extremity Ischemia; Claudication; Rest Pain

Summary: a retrospective review with four year followup on patients that had previously been enrolled in a study to evaluate blockages in the lower legs. the study looked at patients that had undergone a bypass of the leg from the groin to the knee area with an incision in each area using general anesthesia. these patients were compared to others who had undergone treatment with balloon dilatation and stents in the arteries in the thighs with only numbing medicine. the study was completed two years ago and was initially designed to look at outcomes at 24 months. now the investigators are trying to go back and look at outcomes of these patients' treatment at 4 years by simply reviewing their records.


Eligibility criteria:
inclusion criteria: * symptomatic lower extremity ischemia patients treated by femoral-popliteal bypass or percutaneous covered stent graft in previous prospective study exclusion criteria: * na

Keywords: atherosclerosis covered stent percutaneous intervention stent angioplasty
an observational study to gather real-world user feedback on diprobase® advanced eczema cream in adults and children with eczema or dry skin

Conditions: Dermatitis, Atopic

Summary: this is an observational study which means only data are collected from participants about their experience and symptoms, who received their usual treatment without any intervention from the study sponsor. atopic dermatitis, also known as eczema, is a long-lasting skin disease that causes redness, swelling, dryness, cracking, and intense itching. xerosis is the scientific wording to describe dry skin. this condition is caused by a weakened skin barrier that does not hold moisture well. diprobase® advanced eczema cream is already available for use in the uk. it moisturizes and protects the skin. this study is being done to understand how people use diprobase® advanced eczema cream and how consistently they adhere to its recommended use in their daily routines. in this study, participants will be asked to fill in an online questionnaire about their eczema symptoms and experience with diprobase® advanced eczema cream. no treatment advice will be given as a part of this study. the main purpose of this study is to gather feedback from people in the uk who have used diprobase® advanced eczema cream to treat their eczema or their dry skin condition. to do this, researchers will collect the following information from participants: * intensity of eczema symptoms * whether the cream provides a cooling or soothing effect * whether the cream helps to ease the symptoms like itchiness, pain, or dryness it is planned to identify and collect user data from november 2024 to january 2025. participants will be recruited through a consumer database available with an external partner or via social media. in this study, only data are collected. no visits or tests are required as part of this study.


Eligibility criteria:
inclusion criteria: participants: * biological sex: m/f. * age: \> or equal to 18 years of age. * mothers, fathers, grandparents, and other caregivers aged 18 years of age and above, who will report data on themselves, their children from 2 to 12 years of age or their infants under 2 years of age. * able to read and understand the language of the online questionnaire. * have used the product within the previous three (3) months. * agree that the data collected can be used for research, marketing and regulatory purposes. exclusion criteria: * due to the real-world nature of the study, there are no exclusion criteria.

Keywords: dry skin / xerosis
less discomfort and less pharmacology. cataract surgery at physiologic intraocular pressure (iop)

Conditions: Nuclear Cataract

Summary: to investigate the impact of high vs low intraocular pressure (iop) on the intraoperative experience for the patient and surgeon. operating at a more physiologic iop using active sentry hand piece during cataract surgery will result in significantly less discomfort/pain as assessed by the decreased need for rescue medication

objectives: to investigate the impact of intraocular pressure (iop) high vs low on the intraoperative experience for the patient and surgeon design: prospective, single-surgeon, subject's first eyes undergoing phacoemulsification will be randomized to high (intraocular pressure (iop) 65 millimeters of mercury (mmhg)) or low (iop 25mmhg) iop, contralateral eye will receive other treatment hypothesis: operating at a more physiologic iop using active sentry hand piece during cataract surgery will result in significantly less discomfort/pain as assessed by the decreased need for rescue medication

Eligibility criteria:
inclusion criteria: * visually significant cataract 2-3+ undergoing uncomplicated cataract surgery * unremarkable ocular health but inclusive of early age related macular degeneration (amd). exclusion criteria: * history of ocular surgery including corneal refractive surgery * compromised zonular integrity or stability * uncontrolled diabetes and diabetic retinopathy * small pupils * history of systemic inflammatory disease/uveitis * history of psychiatric illness, chronic pain/narcotics, benzodiazepine usage * abnormal liver or renal function
evaluation of a dietary supplement containing melissa officinalis formulated in phospholipids on mood well-being and cortisol modulation

Conditions: Stress; Mood Disorders; Emotional Well-being

Summary: this is a randomized, double-blind, placebo-controlled pilot study designed to evaluate the effect of an oral nutritional supplement containing melissa officinalis formulated in phospholipids on mood and cortisol levels in healthy adults. participants will be randomly assigned to receive either the active supplement or a placebo daily for 3 weeks. the primary outcome measures include changes in mood well-being, perceived stress, and salivary cortisol levels. the study aims to assess both efficacy and safety of the supplement in modulating stress response and emotional balance.


Eligibility criteria:
inclusion criteria: * age between 18 and 65 years * healthy volunteers as assessed by medical history and physical examination * willingness to comply with the study procedures exclusion criteria: * current use of medications or supplements that may affect mood or cortisol levels * known allergy or sensitivity to melissa officinalis or phospholipids * history of psychiatric disorders (e.g., major depression, anxiety disorders) * significant comorbidities (e.g., cardiovascular, hepatic, renal diseases) * pregnant or breastfeeding women * participation in another clinical trial in the past 30 days
minimal residual disease in peripheral t-cell lymphoma

Conditions: Peripheral T Cell Lymphoma

Summary: as t-cell receptor sequencing by lymphotrack is an assay with high sensitivity that can be performed in peripheral blood, the investigators wish to evaluate the ability of this assay to predict which patients are at higher risk of relapse after initial therapy for peripheral t-cell lymphomas which is being given for curative intent. additionally, as more is known about the ability of dynamic monitoring of cfdna in b-cell lymphomas to predict relapse, the investigators wish to explore the use of this technology in t-cell lymphomas.


Eligibility criteria:
inclusion criteria: * at least 18 years of age. * histologically-confirmed peripheral t-cell lymphoma being treated with curative intent. eligible histologies include, but are not limited to: peripheral t-cell lymphoma, not otherwise specified; angioimmunoblastic t-cell lymphoma; anaplastic large cell lymphoma, alk negative; and anaplastic large cell lymphoma, alk positive. * plan for treatment with frontline multi-agent anthracycline containing chemotherapy for curative intent (for example, chop, choep, epoch). a frontline therapy program can include different sequential phases of treatment, including high-dose therapy and autologous stem cell transplantation. * availability of pre-treatment test specimen from bone marrow, blood, lymph node, or alternate site to identify tumor-specific clonotype, or willingness to undergo biopsy if sufficient tissue is not available at time of enrollment (e.g. 15 slides from fixed formalin-fixed paraffin embedded tumor tissue \*patients who have less than 15 slides of fixed formalin-fixed paraffin embedded tumor tissue may be considered for enrollment after discussion with the study principal investigator * able to understand and willing to sign an irb approved written informed consent document. exclusion criteria: * receiving second line of therapy or greater. * diagnosis of primary cutaneous t-cell lymphoma, extranodal nk-cell lymphoma, acute t-cell lymphoma/leukemia, hepatosplenic t-cell lymphoma.
influence of atorvastatin on psoriasis severity and endothelial function

Conditions: Psoriasis

Summary: patients with psoriasis seem to have increased risk for developing atherosclerosis. this may be due to the fact that psoriasis and atherosclerosis are both caused by inflammation and involvement of cells of the immune system. atherosclerosis is frequently treated by statins (class of cholesterol lowering drugs), which lower bad cholesterol levels and also reduce inflammation. some new evidences also suggest that therapy with statins may improve psoriasis skin disease. the current study aims are to evaluate whether a strong statin named atorvastatin can improve psoriatic skin disease and functioning of the arteries. the study also aims to evaluate if the activity of these two diseases are related to levels of common inflammatory biomarkers (substance in blood) and whether atorvastatin can change their levels.


Eligibility criteria:
inclusion criteria: * patients older than 20 years * patients with psoriasis of at least 3-years duration * current moderate to severe psoriatic disease (pasi ≥12, iga≥3) * statin-naïve patients * no history of cardiovascular disease (ischemic heart disease, peripheral vascular disease or cerebrovascular disease) * ldl levels * ldl level \> 70 mg% and \< 160 mg% in low risk patients (defined as having none or a single risk factor\*) * ldl \> 70 mg% and \< 130 mg% in moderate risk patients (defined as the presence of 2 or more risk factors\*) * ldl \> 70 mg% and \< 100 mg% in patients with type ii diabetes * hscrp ≥ 1 mg/l \* risk factors: smoking, hypertension (blood pressure \> 140/90 or current treatment with blood pressure lowering agents, hdl \< 40 mg%, family history of premature coronary artery disease in a first degree relative younger than 45 (men) or 55 (women) and obesity (bmi ≥ 30). exclusion criteria: * current statin therapy * patents with atrial fibrillation * elevated liver enzymes (\> x3 uln) * history of statin-induced liver enzyme elevation * elevated cpk levels (\> x3 uln) * history of myopathy including statin-induced * severe chronic renal failure (gfr \<30 ml/min) * pregnant or breast-feeding women * individuals at risk for poor protocol, or medication compliance * patients with life-expectancy of less than 2 years * patients who are currently participating in another clinical trial * other current active inflammatory and/or infectious conditions * sensitivity to any of atorvastatin ingredients * concomitant drug therapy, taken on a regular basis, which may interact with atorvastatin

Keywords: cardiovascular diseases pharmacologic actions endothelial function dermatology inflammatory disease skin disease
balance tele-rehab in parkinson's disease parkinson's disease

Conditions: Parkinson Disease

Summary: this project will determine the feasibility and efficacy of remote assessment and treatment of balance disorders in people with parkinson's disease.

this project consists of a virtual balance assessment which will use objective measures of balance and gait obtained with wearable sensors on the feet and waist. during a virtual assessment, the modified instrumented stand and walk test (isaw) will be conducted in 80 people with parkinson's disease (pd) to predict a gold-standard, clinical in-person assessment of balance, the mini-balance evaluation system test (mini-bestest). for the balance rehabilitation there will be 80 participants randomized into two groups: 1) unsupervised home agility boot camp (abc) exercises (standard of care), 2) telerehabilitation with therapist conducting the abc exercise program. mobility during daily life will be measured using wearable sensors to explore if improvements after rehabilitation transfer to daily life mobility. the long-term goal of this project is to develop a more effective, home-based balance assessment and treatment that can be used in older adults with balance impairments to improve safe mobility during daily life.

Eligibility criteria:
inclusion criteria: 1. diagnosis of idiopathic pd from movement disorders neurologist with the united kingdom brain bank criteria of bradykinesia and one or more of the following - rest tremor, rigidity, and balance problems not from visual, vestibular, cerebellar or proprioceptive conditions 2. responsive to levodopa (self-reported) 3. hoehn \& yahr stages i-iii; 4. ages 55-85 years old 5. ability to follow directions in order to participate in testing procedures and exercise classes 6. free of any medical conditions or medication that contraindicates participation in an exercise program 7. willing and able to participate in rehabilitation intervention approximately 3x/week for 4 weeks while also refraining from making changes to medications (as reasonable) or to other exercise programs during the study period. exclusion criteria: 1. major musculoskeletal or neurological disorders, structural brain disease, epilepsy, acute illness or health history, other than pd, significantly affecting gait and balance (i.e., musculoskeletal disorder, vestibular problem, head injury, stroke, cardiac disease, etc.) 2. no medical condition that precludes exercise 3. cognitive inability to participate in an exercise program, such as moca score less than or equal to 19, prior diagnosis of dementia or inability to follow directions 4. recurrent fallers, defined as those who fall more than 3 times a week (from patient and caregiver recollection) 5. excessive use of alcohol or recreational drugs 6. recent change in medication 7. inability to stand and walk for isaw without an assistive device.

Keywords: tele-rehabilitation balance mobility tele-assessment wearable-sensors
a trail of second-line chemotherapy sequential nkg2d car-nk cell therapy for pancreatic cancer

Conditions: Pancreatic Cancer Non-resectable

Summary: this is a single-center, single-arm, open-label, dose-escalation clinical study to evaluate the safety and anti-tumor efficacy of second-line systemic chemotherapy sequential nkg2d car-nk cell therapy for pancreatic cancer


Eligibility criteria:
inclusion criteria: * 1. age between 18\~75 years old (including boundary value), both male and female. * 2. histologically or cytologically confirmed pancreatic ductal adenocarcinoma or ipmn carcinosis with at least first-line systemic therapy failure. * 3. zubrod-ecog-who score (see annex 2) on a scale of 0-2. * 4. life expectancy of at least 3 months at screening, as judged by the investigator. * 5. at least one stably evaluable target lesion according to recist1.1 criteria. * 6. subject has adequate organ and bone marrow function. laboratory screening results should be within the stable range described below, with no ongoing supportive care (\&#34;yellowing\&#34; therapy such as ptcd, enbd, or bile duct stenting is allowed when pancreatic cancer invades the common bile duct). * 7. remission of all toxicities due to prior antineoplastic therapy to grade 0\~1 (according to nci ctcae version 5.0) or to acceptable levels for inclusion/exclusion criteria. * 8. childbearing status: not pregnant, and if of childbearing potential, willing to use effective contraception from the time of signing the informed consent form to 6 months after the last cell infusion (females of childbearing potential include premenopausal females and females within 2 years of postmenopause). * 9. subjects must sign and date written informed consent. * 10. subjects must be voluntary and able to comply with predetermined treatment regimens, laboratory tests, follow-up, and other study requirements. exclusion criteria: * 1. pregnant and lactating females. * 2. positive serology for hiv, treponema pallidum or hcv (those who are hcv antibody positive but hcv-rna negative, stable syphilis and inactive patients can be included). * 3. any active infection, including but not limited to active tuberculosis, hbv infection (including hbsag positive, or hbcab positive with hbv dna above the lower limit of laboratory testing), epstein-barr virus (ebv) dna positive, cytomegalovirus (cmv) dna positive or novel coronavirus (new coronavirus) nucleic acid positive, and other bacterial, viral, or fungal infections requiring drug treatment; * 4. history of malignancy within 5 years, with the exception of basal cell carcinoma of the skin and carcinoma in situ of the cervix. * 5. any other health condition that, in the judgment of the investigator, would preclude participation in the study.
open-label study of safety of h1337 in healthy volunteers

Conditions: Glaucoma Open-Angle Primary; Ocular Hypertension

Summary: the trial will evaluate the safety of one dose regimen of h-1337 \[1% twice daily (b.i.d.)\] in both eyes in healthy volunteers.


Eligibility criteria:
inclusion criteria: * healthy adult male or female subjects * subjects in good ocular and systemic health with clinically insignificant medical and ophthalmic history exclusion criteria: * chronic or acute ophthalmic disease in each eye including but not limited to any form of glaucoma, retinal diseases, clinically significant cataract (primary or secondary) * recent intraocular surgery in either eye (within 6 months) note: other inclusion/exclusion criteria apply.
a pilot study of rise for nurse managers

Conditions: Self Compassion; Stress; Burn-Out

Summary: the purpose of this study is to determine whether rise for nurse managers has a significant impact on nurse managers' post-traumatic growth, resilience, insight, self-compassion, and empowerment, as well as mental well-being, in their personal lives and their working environment.


Eligibility criteria:
inclusion criteria: 1. adult ≥ 18 years old 2. licensed as an rn 3. nurse manager employed by adventhealth in a hospital-based setting at the altamonte springs, apopka, carrollwood, celebration, connerton, dade city, daytona beach, deland, east orlando, fish memorial, heart of florida, kissimmee, lake placid, lake wales, new smyrna beach, north pinellas, ocala, orlando, palm coast, sebring, tampa, waterman, wauchula, wesley chapel, winter garden, winter park, or zephyrhills campus 4. able to speak, read, and understand english fluently 5. able to provide informed consent 6. willing and able to comply with all study procedures and requirements for the duration of the study exclusion criteria: 1. employed as a direct care nurse or in another level of nursing leadership (i.e., assistant nurse manager, director of nursing, executive leader)
neurological sequelae in patients with acute carbon monoxide poisoning

Conditions: Carbon Monoxide Poisoning

Summary: the purpose of this study is to access the clinical characteristics and risk factors for neurological sequelae after acute carbon monoxide poisoning.

after being informed about the study and potential risks, patients meet the inclusion criteria would be given informed consent and entry the study. the data will be collected according to self-designed questionnaire, including :1) the baseline characteristics: would be recorded 6 hours after patients presentation;2) patients' self evaluation for discomfort symptoms: would be recorded at day 0, week 1, 3 and 6, month 6 and 12；3) neurological function: would be recorded at day 0, week 6, month 6 and 12.

Eligibility criteria:
inclusion criteria: * patients present within 12 hours after acute carbon monoxide poisoning; * age older than 16 years. exclusion criteria: * pregnant women； * patients receive oxygen therapy before presentation; * have history of acute carbon monoxide poisoning within 1 year; * have been diagnosed any of the following disease: parkinson disease; cognitive disorder, psychiatric disorders, sequelae of cerebral infarction or hemorrhage, chronic kidney disease and receive hemodialysis, congestive heart failure ( nyha class iii-iv)

Keywords: carbon monoxide poisoning neurological sequelae